Tiragolumab for B-Cell Lymphoma
This trial is testing a new immunotherapy drug to see if it's safe and works well against certain blood cancers.
- B-Cell Lymphoma
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are eligible to join this clinical trial?
"Correct. Clinicaltrials.gov indicates that the research was first published on July 22, 2019 and recently updated November 22, 2022. The trial is presently seeking 60 volunteers to be recruited across 7 sites."
Is there a call for participants in this research endeavor?
"Aye, the details provided on clinicaltrials.gov appear to show that this medical trial is still accepting applicants. It was initiated on July 22nd 2019 and updated as recently as November 22nd 2022, with a total of 60 participants being recruited across 7 different research sites."
Has Tiragolumab been accorded official clearance by the FDA?
"Due to limited data regarding its safety and efficacy, tiragolumab has been given a score of 1 on our scale. This is typical for phase 1 clinical trials."
Have other research endeavors implemented Tiragolumab?
"Tiragolumab's first trial was conducted at the National Institutes of Health Clinical Centre in 1993. Since then, 959 trials have been completed and a further 905 are still recruiting participants, with Nashville, Tennessee being one of their main sites for research."
Where are the most prominent locales for this trial in Canada?
"Patients may be enrolled in this medical study at SCRI located in Nashville, Tennessee; Oncology Hematology Care Inc. (OHC) of Cincinnati, Ohio; Colorado Blood Cancer Institute (CBCI), which is part of Presbyterian/ St. Luke's Medical Center situated in Denver and seven other sites across the country."
What conditions can Tiragolumab be employed to alleviate?
"Tiragolumab is frequently prescribed for chronic lymphocytic leukemia, but also has the potential to help patients who have not responded well to tnf antagonist therapies or had a suboptimal response from prior systemic treatments such as chemotherapy."